Usability, safety, efficacy, positioning of the Atlas drug-eluting coronary stent: Evaluation of preliminary perioperative results

Abstract

Abstract Background: Coronary artery disease (CAD) is the most common type of heart disease. For its revascularization, minimally invasive techniques have been the preferred treatment modality for the past two decades. However, restenosis is a significant issue after these techniques. Drug-eluting stents (DES), primarily sirolimus or paclitaxel- releasing, have started to be widely used to reduce the rate of restenosis. Material Methods: 30 patients, 51-83 years old, who demonstrated significant coronary artery stenosis were treated with the The ATLAS Drug Eluting Coronary Stent System (AtlasPTCAⓇ; Invamed, Ankara, Turkey) at the Medical Simulation and Training Center, MU Plovdiv, Bulgaria. Accurate positioning of the stent, which contains radiopaque tungsten-tantalum markings at the tips, was traced by angiographical imaging. Measurements of vessel sizes before and after treatment were performed using quantitative coronary assessment (QCA). Quantitative analysis was performed by comparing the diameter of the reference vessel. Data were analyzed using IBM SPSS statistical package version 25 program. Result: After treatment, the final lumen diameter value was 3.45±0.56 mm, similar to the diameter measurement of the reference vessel. Restenosis was not observed in any of the patients. No serious side effects are observed. Conclusions AtlasPTCAⓇ is feasible and associated with a favorable profile of safety, efficacy, deliverability, and usability. Therefore, its use can provide a valuable aid in the treatment of coronary artery disease. For long-term evaluation, more studies are needed.